{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:08:59Z","timestamp":1772003339795,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M752329"],"award-info":[{"award-number":["2024M752329"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SuZhou Municipal Health Commission Project","award":["SKY2022165"],"award-info":[{"award-number":["SKY2022165"]}]},{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202217"],"award-info":[{"award-number":["JY202217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00737-026-01679-1","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:03:12Z","timestamp":1769824992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic safety assessment of zuranolone: real-world adverse event analysis from the FAERS database"],"prefix":"10.1007","volume":"29","author":[{"given":"Kun","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","volume":"26","author":"EG Brown","year":"2003","unstructured":"Brown EG (2003) Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA). Drug Saf 26:145\u2013158","journal-title":"Drug Saf"},{"key":"1679_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2806","volume":"37","author":"A Bullock","year":"2022","unstructured":"Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, Silber C, Kanes SJ, Jonas J, Doherty J (2022) A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol 37:e2806","journal-title":"Hum Psychopharmacol"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/d41591-023-00032-8","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T (2023) New depression drug zuranolone one step closer to FDA ruling. Nat Med 29:1032\u20131033","journal-title":"Nat Med"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41398-023-02514-2","volume":"13","author":"AJ Cutler","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Maletic V (2023) Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry 13:228","journal-title":"Transl Psychiatry"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78:951\u2013959","journal-title":"JAMA Psychiatry"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"22m14475","DOI":"10.4088\/JCP.22m14475","volume":"84","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Citrome L, Huang MY, Acaster S, Fridman M, Bonthapally V, Lasser R, Kanes SJ (2023a) Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression. J Clin Psychiatry 84:22m14475","journal-title":"J Clin Psychiatry"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J (2023b) Zuranolone for the treatment of postpartum depression. Am J Psychiatry 180:668\u201367","journal-title":"Am J Psychiatry"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH (2019) Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102:75\u201390","journal-title":"Neuron"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/02698811241282777","volume":"38","author":"J Dunbar","year":"2024","unstructured":"Dunbar J, Walling DP, Hassman HA, Jain R, Czysz A, Nandy I, Ona V, Moseley MK, Levin S, Maruff P (2024) Cognitive effects, pharmacokinetics, and safety of Zuranolone administered alone or with Alprazolam or ethanol in healthy adults in a phase 1 trial. J Psychopharmacol 38:1122\u20131136","journal-title":"J Psychopharmacol"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","volume":"39","author":"E Engin","year":"2018","unstructured":"Engin E, Benham RS, Rudolph U (2018) An emerging circuit pharmacology of GABA(A) receptors. Trends Pharmacol Sci 39:710\u2013732","journal-title":"Trends Pharmacol Sci"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev-pharmtox-032320-015420","volume":"61","author":"S Ghatak","year":"2021","unstructured":"Ghatak S, Talantova M, McKercher SR, Lipton SA (2021) Novel therapeutic approach for excitatory\/inhibitory imbalance in neurodevelopmental and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 61:701\u2013721","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93:539\u2013546","journal-title":"Clin Pharmacol Ther"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41467-018-05125-4","volume":"9","author":"HY He","year":"2018","unstructured":"He HY, Shen W, Zheng L, Guo X, Cline HT (2018) Excitatory synaptic dysfunction cell-autonomously decreases inhibitory inputs and disrupts structural and functional plasticity. Nat Commun 9:2893","journal-title":"Nat Commun"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-023-01953-x","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Zuranolone: first approval. Drugs 83:1559\u20131567","journal-title":"Drugs"},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","volume":"92","author":"A Joshi","year":"2025","unstructured":"Joshi A, Gawey L, Saadi C, Naidoo P, Rick JW, Park SY, Cogen AL, Daveluy SD, Hsiao JL, Shi VY (2025) Postmarketing safety surveillance of adalimumab, secukinumab, and Infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database. J Am Acad Dermatol 92:1434\u20131435","journal-title":"J Am Acad Dermatol"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acsmedchemlett.3c00388","volume":"14","author":"RB Kargbo","year":"2023","unstructured":"Kargbo RB (2023) Neurosteroids and postpartum depression: the mechanism, efficacy, and approval of Brexanolone and Zurzuvae. ACS Med Chem Lett 14:1326\u20131328","journal-title":"ACS Med Chem Lett"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/jcm14072418","volume":"14","author":"Z Khamidullina","year":"2025","unstructured":"Khamidullina Z, Marat A, Muratbekova S, Mustapayeva NM, Chingayeva GN, Shepetov AM, Ibatova SS, Terzic M, Aimagambetova G (2025) Postpartum depression epidemiology, risk factors, diagnosis, and management: an appraisal of the current knowledge and future perspectives. J Clin Med 14:2418","journal-title":"J Clin Med"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/phar.2331","volume":"39","author":"LD Leader","year":"2019","unstructured":"Leader LD, O\u2019Connell M, VandenBerg A (2019) Brexanolone for postpartum depression: clinical evidence and practical considerations. Pharmacotherapy 39:1105\u20131112","journal-title":"Pharmacotherapy"},{"key":"1679_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115640","volume":"331","author":"Z Li","year":"2024","unstructured":"Li Z, Wu Q, Peng P, Wu M, Liu S, Liu T (2024) Efficacy and safety of zuranolone for the treatment of depression: a systematic review and meta-analysis. Psychiatry Res 331:115640","journal-title":"Psychiatry Res"},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12311-025-01873-4","volume":"24","author":"H Liu","year":"2025","unstructured":"Liu H, Fan D, Tao H, Shen Z, Yao K (2025a) Characteristics of adverse events and clinical risks of Omaveloxolone based on FAERS data. Cerebellum 24:119","journal-title":"Cerebellum"},{"key":"1679_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110581","volume":"171","author":"H Liu","year":"2025","unstructured":"Liu H, Fan D, Tao H, Shen Z, Yao K (2025b) Real-world safety profile of Fenfluramine in refractory epilepsy: a pharmacovigilance study based on FAERS database. Epilepsy Behav 171:110581","journal-title":"Epilepsy Behav"},{"key":"1679_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tips.2023.06.009","volume":"44","author":"B Luscher","year":"2023","unstructured":"Luscher B, Maguire JL, Rudolph U, Sibille E (2023) GABA(A) receptors as targets for treating affective and cognitive symptoms of depression. Trends Pharmacol Sci 44:586\u2013600","journal-title":"Trends Pharmacol Sci"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/13696998.2024.2334160","volume":"27","author":"S Meltzer-Brody","year":"2024","unstructured":"Meltzer-Brody S, Gerbasi ME, Mak C, Toubouti Y, Smith S, Roskell N, Tan R, Chen SS, Deligiannidis KM (2024) Indirect comparisons of relative efficacy estimates of Zuranolone and selective serotonin reuptake inhibitors for postpartum depression. J Med Econ 27:582\u2013595","journal-title":"J Med Econ"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.64719\/pb.4169","volume":"37","author":"CB Nemeroff","year":"2003","unstructured":"Nemeroff CB (2003) The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37:133\u2013146","journal-title":"Psychopharmacol Bull"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/11589420-000000000-00000","volume":"25","author":"N Perroud","year":"2011","unstructured":"Perroud N (2011) Suicidal ideation during antidepressant treatment: do genetic predictors exist? CNS Drugs 25:459\u2013471","journal-title":"CNS Drugs"},{"key":"1679_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03721-4","volume":"15","author":"AB R","year":"2024","unstructured":"R AB, K SR, Chandran D, Hegde S, Upadhya R, Se PK, Shenoy S, Devi V, Upadhya D (2024) Cell-specific extracellular vesicle-encapsulated exogenous GABA controls seizures in epilepsy. Stem Cell Res Ther 15:108","journal-title":"Stem Cell Res Ther"},{"key":"1679_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1755-5949.2010.00160.x","volume":"16","author":"RR Reeves","year":"2010","unstructured":"Reeves RR, Ladner ME (2010) Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16:227\u2013234","journal-title":"CNS Neurosci Ther"},{"key":"1679_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1176\/appi.ajp.159.4.663","volume":"159","author":"G Sanacora","year":"2002","unstructured":"Sanacora G, Mason GF, Rothman DL, Krystal JH (2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159:663\u2013665","journal-title":"Am J Psychiatry"},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/ebmh.13.2.52","volume":"13","author":"F Seem\u00fcller","year":"2010","unstructured":"Seem\u00fcller F, M\u00f6ller HJ, Obermeier M, Schennach-Wolff R, Riedel M (2010) Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years. Evid Based Ment Health 13:52","journal-title":"Evid Based Ment Health"},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-med-041217-011106","volume":"70","author":"DE Stewart","year":"2019","unstructured":"Stewart DE, Vigod SN (2019) Postpartum depression: pathophysiology, treatment, and emerging therapeutics. Annu Rev Med 70:183\u2013196","journal-title":"Annu Rev Med"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","volume":"76","author":"K Tada","year":"2020","unstructured":"Tada K, Maruo K, Isogawa N, Yamaguchi Y, Gosho M (2020) Borrowing external information to improve bayesian confidence propagation neural network. Eur J Clin Pharmacol 76:1311\u20131319","journal-title":"Eur J Clin Pharmacol"},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","volume":"32","author":"P Trillenberg","year":"2023","unstructured":"Trillenberg P, Sprenger A, Machner B (2023) Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol Drug Saf 32:910\u2013917","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coph.2004.08.006","volume":"5","author":"KA Wafford","year":"2005","unstructured":"Wafford KA (2005) GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 5:47\u201352","journal-title":"Curr Opin Pharmacol"},{"key":"1679_CR35","volume":"6","author":"CA Wilson","year":"2025","unstructured":"Wilson CA, Robertson L, Ayre K, Hendon JL, Dawson S, Bridges C, Khalifeh H (2025) Brexanolone, zuranolone and related neurosteroid GABA(A) receptor positive allosteric modulators for postnatal depression. Cochrane Database Syst Rev 6:Cd014624","journal-title":"Cochrane Database Syst Rev"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr. (2021) Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract 9:819-829.e812","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1679_CR37","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1007\/s12264-021-00689-6","volume":"37","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Wu X, Zhou R, Sie O, Niu Z, Wang F, Fang Y (2021) Hypothalamic-Pituitary-End-Organ axes: hormone function in female patients with major depressive disorder. Neurosci Bull 37:1176\u20131187","journal-title":"Neurosci Bull"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-026-01679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-026-01679-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-026-01679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:24:00Z","timestamp":1772000640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-026-01679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s00737-026-01679-1","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"29"}}